Controls nausea and vomiting associated with certain types of anesthesia and surgery. ANDA 91675, held by Cosette Pharms Nc. Promethazine Hydrochloride.
As of Nov 16, 2026, ANDA 91675 (Promethazine Hydrochloride), held by Cosette Pharms Nc, was first approved by FDA on Jun 28, 2012, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Promethazine Hydrochloride Syrup (Promethazine Hydrochloride Oral Solution, USP) is useful for: Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 28, 2012 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Promethazine Hydrochloride6.25MG/5ML · syrup;oral | Promethazine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters